As part of our series focussing on medicines available in Australia, we have added a product review of the use of bimekizumab for axial spondyloarthritis.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring bimekizumab use to treat axial spondyloarthritis. It provides commentary from Professor Paul Bird, Rheumatologist in private practice and a Conjoint Professor at the University of New South Wales.
Please login below to download this issue (PDF)